Salute e Benessere

Voting Rights and Shares Capital of the Company

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)PARIS, Dec.11, 2024(GLOBE NEWSWIRE) --Paris, France, December 11, 2024Market: Euronext Paris / Nasdaq Euronext Compartment: BISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reuters: NANO.PA Website:www.nanobiotix.comDateNumber of Shares OutstandingTotal number of voting...
Nasdaq GlobeNewswire
11/12/2024

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the…

th, 2024 DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old DBV and FDA aligned on key study design elements for the COMFORT Toddlers study in 1 – 3 year-olds, including study size and wear time collection methodology and analysis COMFORT Toddlers study on-track to initiate in 2Q 2025Viaskin Peanut patch BLA submission for the Toddlers indication anticipated for 2H 2026 FDA confirmed criteria for...
Nasdaq GlobeNewswire
11/12/2024

Iron Supplements Market to Reach USD 5.18 Billion by 2028, Driven by Rising…

This growth is fueled by a rising prevalence of iron deficiency-related disorders, including anemia, across various age groups. Additionally, the growing emphasis on preventive healthcare and dietary supplementation is boosting demand for iron supplements worldwide. As consumers become more health-conscious, the adoption of these products is anticipated to expand, particularly in regions with high instances of nutritional deficiencies. This growth is fueled by a rising prevalence of iron...
PR Newswire
11/12/2024

AB Science will host a live webcast on Monday December 16, 2024, from 5.30pm to…

PRESS RELEASEAB SCIENCE WILL HOST A LIVE WEBCAST ON MONDAY DECEMBER 16, 2024 FROM 5.30PM TO 6.30PM CETParis, 11 December, 2024, 6pm CETAB Science SA(Euronext – FR0010557264 – AB) will host a live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CET. The agenda of this live webcast will be to provide an update on both masitinib and AB8939 platforms.The following attendees will participate to the live webcast: Alain Moussy, co-founder and CEO of AB ScienceOlivier...
Nasdaq GlobeNewswire
11/12/2024

OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage…

OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi®ARTEMIA: Clinical trial protocol approved globally. Most countries and sites activated, with full activation expected in H1 2025. First patients enrolled in this international Phase 3 registration study of Tedopi® in monotherapy in second-line Non-Small Cell Lung Cancer (NSCLC).TEDOVA: Completion of patient enrollment in the Phase 2 study of Tedopi® alone or in combination...
Nasdaq GlobeNewswire
11/12/2024

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as…

Disclosure of Share Capital and Voting Rights Outstandingas of November 30, 2024(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)Paris, France (December 11, 2024 - 6:00 pm)– As of November 30, 2024, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses, breaks...
Nasdaq GlobeNewswire
11/12/2024

Osteotec appointed as exclusive distributor for Cerapedics in the UK and Ireland

The introduction of these clinically validated solutions underscores Osteotec's mission to enhance surgical outcomes and transform patient care in bone repair. The introduction of these clinically validated solutions underscores Osteotec's mission to enhance surgical outcomes and transform patient care in bone repair. Headquartered inWestminster, Colorado, Cerapedics is a global leader in orthopaedics. Its i-FACTOR portfolio is powered by the proprietary P-15 Osteogenic Cell Binding...
PR Newswire
11/12/2024

Radiotherapy Market to Hit USD 9.62 Billion by 2030 with 4.9% CAGR |…

Browse in-depth TOC on "Radiotherapy Market"310 - Tables56 - Figures312 - Pages Browse in-depth TOC on "Radiotherapy Market" 310 - Tables 56 - Figures 312 - Pages Moreover, in recent years, the market players are also focusing on providing cost-effective radiotherapy systems due to its growing demand amongst various end users in the market. Also, there is an increasing demand for radiotherapy specially EBRT in the emerging markets. All these factors are expected to drive…
PR Newswire
11/12/2024

GNT Pharma Reports Significant Improvements in Stroke Patients Treated with its…

SEOUL, South Korea, Dec. 11, 2024 /PRNewswire/ -- GNT Pharma Co. Ltd, a late-stage pharmaceutical company founded in 1998 with offices in Seoul Korea, Italy and USA, announced today the results of its latest Phase II ('SONIC') and Phase III ('Rodin') clinical trials study showing that stroke patients who received early administration of Nelonemdaz in combination with endovascular thrombectomy, demonstrated significant improvements in outcomes. SEOUL, South Korea , Dec. 11, 2024 ...
PR Newswire
11/12/2024

CRO Services Market Surges to USD 188.54 Billion by 2030, Propelled by 12.6%…

The CRO (Contract Research Organization) services market is primarily driven by the increasing demand for outsourced research and clinical trials due to the rising cost and complexity of in-house research. The growing emphasis on drug development, regulatory compliance, and the need for faster market approval are also key contributors to the market's growth. Additionally, advancements in biotechnology and the surge in personalized medicine fuel demand for specialized CRO services. However, the…
PR Newswire
11/12/2024

Coloplast A/S - Trading in Coloplast shares by board members, executives or…

Please see enclosed pdf. Attachment 11122024_trading_in_shares_GL
Nasdaq GlobeNewswire
11/12/2024

Signant Health Names Krishna Maridi, a Finance Leader with Over 25 Years of…

"I've had the benefit of first-hand experience watching Krishna lead through complex process improvement to make a business operate better for its customers and employees," commented Roger Smith, Signant's chief executive officer. "In an environment where our biopharma and CRO customers seek partners that enable greater precision in service delivery based on analytics, his unique combination of pharmaceutical industry knowledge, broad financial expertise, and global business…
PR Newswire
11/12/2024

Noul and Limbach Gruppe, Germany's top lab chain, to sign an agreement for the…

Noul's CEO, David Lim said, "This agreement is significant in that it is the first contract with a major lab chain in Europe," and that "Noul plans to extend the reach into the European market with all of its test portfolios, beginning with the well-referenced miLab MAL and BCM, and in the near future with the cervical cancer solution recognized by WHO-UNITAID. Securing the most esteemed and high-standard reference customers in Europe will accelerate our expansion into other…
PR Newswire
11/12/2024

Genmab to Hold 2024 R&D Update and ASH Data Review Meeting

Media ReleaseEvent to be held virtually via live webcast and archived on www.genmab.comCopenhagen, Denmark; December 11, 2024 –Genmab A/S(Nasdaq: GMAB) will hold its 2024 R&D Update and ASH Data Review Meeting today, December 11, 2024 at 11:00 AM Eastern Time (5:00 PM CET / 4:00 PM GMT).The event will take place virtually in English and can be attended via live webcast. To register for the webcast, clickhttps://genmab-post-ash-2024.open-exchange.net/. An archive...
Nasdaq GlobeNewswire
11/12/2024

KFSHRC Jeddah Performs the First Fully Robotic Liver Transplant in the Western…

JEDDAH, Saudi Arabia, Dec.11, 2024(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) in Jeddah successfully performed the first robotic liver transplant in the Western Region on a 23-year-old man suffering from hereditary chronic progressive liver disease. This landmark achievement underscores KFSHRC's commitment to providing the highest standards of specialized healthcare and the best patient experience within a comprehensive educational and research...
Nasdaq GlobeNewswire
11/12/2024

Teva Announces New Patient Access Program with Direct Relief to Provide Access…

Teva to provide two generic inhaler products to Direct Relief for its network offree andcharitable clinicsThe program , launching this month, will run for a minimum of three yearsPARSIPPANY, N.J., Dec.11, 2024(GLOBE NEWSWIRE) -- Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of a new patient access program, in partnership with Direct Relief, to supply inhalers to eligible...
Nasdaq GlobeNewswire
11/12/2024

GEn1E Lifesciences appoints François Nader, MD as Chair of its Board of…

Former CEO of NPS Pharma brings strong biotech expertise to further accelerate GEn1E's development and commercialization of dual signal modulators as novel precision therapies François Nader, MD, MBA as chair of its Board of Directors, effective immediately."We are thrilled to welcome François to GEn1E's Board of Directors as Chair," saidRitu Lal, PhD, CEO and Co-founder ofGEn1E Lifesciences. "François' deep expertise in biopharmaceutical innovation, strategic leadership, and…
Nasdaq GlobeNewswire
11/12/2024

Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3…

Positive topline data for CAN-2409 viral immunotherapy achieved primary endpoint by demonstrating statistically significant and clinically meaningful benefit when combined with radiation therapy for intermediate-to-high risk, localized prostate cancerThe safety profile of CAN-2409 was generally consistent with previous studies, with no new safety signals identified The phase 3 clinical trial was conducted under a Special Protocol Assessment (SPA) with the FDA NEEDHAM, Mass., Dec...
Nasdaq GlobeNewswire
11/12/2024

Cystatin C Assay Market Expected to Thrive with Increasing Applications in Renal…

IMR
11/12/2024

iOnctura reaches new clinical milestones in uveal melanoma

Roginolisib is being investigated in solid and hematological malignancies including uveal melanoma (UM), a rare cancer of the eye. Eye melanoma is a rapidly growing market which is projected to be worth USD 9.56B by 2032[1]. Roginolisib is being investigated in solid and hematological malignancies including uveal melanoma (UM), a rare cancer of the eye. Eye melanoma is a rapidly growing market which is projected to be worthUSD 9.56Bby 2032[1] . The two-partPhase I studyDIONE-01,...
PR Newswire
11/12/2024

PRESERVE Project to Host Final Event to Showcase Sustainable Packaging…

BERLIN, Dec.11, 2024(GLOBE NEWSWIRE) -- The PRESERVE Project, an innovative Horizon 2020 initiative, is hosting its final event as a side gathering to the European Bioplastics Conference on 12 December. This milestone event will highlight the project's groundbreaking achievements, avant-garde breakthroughs, and a forward-looking roadmap for the future of sustainable packaging.The day will open with a welcome address by Dr. Aldo R. Reyes, the Project Coordinator, setting the stage for...
Nasdaq GlobeNewswire
11/12/2024

Kanazawa University research: How Cells Repair DNA's Protective Barrier: A…

This slower response poses significant challenges, especially in diseases like Hutchinson–Gilford Progeria Syndrome (HGPS). In HGPS, a mutation in the LMNA gene produces progerin, a defective variant of lamin A that remains permanently associated with the NE and disrupts repair mechanisms (Fig. 1). Because progerin's impaired mobility reduces the reserve pool available for repair, cellular damage could be further compounded, contributing to accelerated aging symptoms in patients. This slower...
PR Newswire
11/12/2024

Bulletin from Sobi's Extraordinary General Meeting (EGM)

Sobi Sobi Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees acrossEurope,North America, theMiddle East,AsiaandAustralia. In 2023, revenue amounted toSEK 22.1 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at...
PR Newswire
11/12/2024

EQT Life Sciences Leads Series B Extension in Noema Pharma, Raising Total Series…

Proceeds from the financing will drive the continued development of Noema Pharma's clinical-stage assets, including its lead candidate basimglurant (NOE-101), a mGluR5 inhibitor currently in Phase 2 trials for severe pain in trigeminal neuralgia (TN) and seizures in tuberous sclerosis complex (TSC). Additionally, the Company is advancing gemlapodect (NOE-105), a PDE10a inhibitor in Phase 2 for Tourette syndrome and childhood onset fluency disorder (COFD or stuttering), as well as NOE-115, a…
PR Newswire
11/12/2024
Altri  Comunicati